Lipid Forum 2023: Examining the Role of Lp(a) as a Risk Factor

Course Chair


Past President, National Lipid Association

Director, Division of Cardiology

Advocate Heart Institute at Advocate Lutheran General Hospital

Park Ridge, IL

Clinical Associate Professor, Loyola Stritch School of Medicine

Chicago, IL

Series Faculty
Marlys Koschinsky PhD, FAHA, FNLA, FACC, FACHS

Marlys Koschinsky, PhD, FAHA, FNLA, FACC, FACHS

Professor, Department of Physiology and Pharmacology

Scientist, Robarts Research Institute

Schulich School of Medicine and Dentistry

University of Western Ontario

London, Ontario Canada

Patrick M. Moriarty, MD

Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC

Professor of Medicine and Clinical Pharmacology

Director of Atherosclerosis and Lipid-apheresis Center

University of Kansas Medical Center

Kansas City, KS

Jessica M. Peña, MD, MPH, FNLA, FACC

Jessica M. Peña, MD, MPH, FNLA, FACC

Associate Professor of Clinical Medicine

Associate Professor of Medicine in Clinical Radiology

Weill Cornell Medical College

New York, NY

James A. Underberg, MS, MD, FACP, FACPM, MNLA

James A. Underberg, MD, MS, FACP, FACPM, FASH, MNLA

Clinical Assistant Professor of Medicine

NYU School of Medicine & NYU Center for CV Prevention

Director Bellevue Hospital Lipid Clinic

Past-President National Lipid Association

Past-President American Board of Clinical Lipidology

Diplomate American Board of Clinical Lipidology

New York, NY

Contact Us

Vindico Medical Education
6900 Grove Road
Thorofare, NJ 08086

Email Us

These continuing education activities are provided by
Vindico Medical Education

Educational Partner
Purdue University College of Pharmacy

These activities are supported by an educational grant from Novartis Pharmaceuticals Corporation.

CE Webinar

Current and Emerging Therapies to Reduce Lp(a)

Saturday, February 25, 2023 | 10:00 am – 12:30 pm ET


  • Current Approaches to Reduce Lp(a)
  • Emerging Therapies for Lp(a) Reduction
  • Panel Discussion: Lp(a), Therapeutic Landscape, and CV Risk
  • Clinical Cases
  • LIVE Question & Answer
Register Now!

Series Overview

Lipoprotein(a) [Lp(a)] is a low-density lipoprotein particle that is associated with poor cardiovascular prognosis due to its pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Unfortunately, traditional lipid-lowering therapy does not provide sufficient Lp(a) reduction. High levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Despite its demonstrated contribution to atherosclerotic cardiovascular disease burden, there is a lack of standardization and harmonization of assays, universal guidelines for diagnosing and providing risk assessment, and targeted treatments to lower Lp(a). In this CE program, expert faculty review the pathophysiology and accurate measurement of Lp(a), implications of increased Lp(a) levels on cardiovascular risk, as well as current and emerging therapeutic approaches to manage patients with elevated Lp(a). These sessions, incorporate didactic presentations covering the pathophysiology of Lp(a), current and emerging therapies for Lp(a) reduction, associated risks, guidelines, clinical cases, and the patient experience, as well as including a live question-and-answer session.

Target Audience

The intended audience for these activities are cardiologists, endocrinologists, lipidologists, internists, family medicine physicians, pharmacists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with cardiovascular risk factors.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the structure and pathophysiology of Lp(a).
  • Review the role of Lp(a) as a risk factor in atherosclerotic cardiovascular disease.
  • Outline the current approaches to treat patients with elevated Lp(a).
  • Summarize the emerging therapies for the management of patients with elevated Lp(a).
  • Outline the challenges and modalities involved in the measurement of Lp(a).
  • Assess the significance of Lp(a) as a tool for cardiovascular risk assessment.
  • Examine evidence-based strategies to identify patients who are at risk for cardiovascular events and may benefit from reduction of Lp(a).